PharmacoEconomics - Open

2017 - 2025

Current editor(s): Timothy Wrightson and Christopher Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 2, issue 4, 2018

Including Future Consumption and Production in Economic Evaluation of Interventions that Save Life-Years: Commentary pp. 357-358

Erik Nord and Christoffer Lamøy

Longitudinal Effects of Adjuvant Endocrine Therapy on the Quality of Life of Post-menopausal Women with Non-metastatic ER+ Breast Cancer: A Systematic Review pp. 359-369

Hong Xiao, Xinyi Jiang, Cheng Chen, Alberto J. Montero and Vakaramoko Diaby

Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events pp. 371-380

Laurence M. Djatche, Stefan Varga and Robert Lieberthal

Functional Status and Well-Being in People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Compared with People with Multiple Sclerosis and Healthy Controls pp. 381-392

Caroline C. Kingdon, Erinna W. Bowman, Hayley Curran, Luis Nacul and Eliana M. Lacerda

Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014 pp. 393-402

David Nathanson, Ugne Sabale, Jan W. Eriksson, Thomas Nyström, Anna Norhammar, Urban Olsson and Johan Bodegård

Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease pp. 403-413

James Lomas, Miqdad Asaria, Laura Bojke, Chris P. Gale, Gerry Richardson and Simon Walker

Out-of-Pocket Household Expenditures on Medical Injections in Cambodia pp. 415-421

Sachiko Ozawa, Tatenda T. Yemeke, Alie F. Tawah, Vivek Kulkarni and Manuela Villar Uribe

Utilization and Expenditure of Anti-cancer Medicines in Kosovo: Findings and Implications pp. 423-432

Arianit Jakupi, Brian Godman, Antony Martin, Alan Haycox and Indrit Baholli

The Healthcare Cost Burden of Acute Myocardial Infarction in Alberta, Canada pp. 433-442

Dat T. Tran, Arto Ohinmaa, Nguyen X. Thanh, Robert C. Welsh and Padma Kaul

An Exploratory Study: A Head-to-Head Comparison of the EQ-5D-5L and AQoL-8D for Long-Term Publicly Waitlisted Bariatric Surgery Patients Before and 3 Months After Bariatric Surgery pp. 443-458

Julie Campbell, Martin Hensher, Amanda Neil, Alison Venn, Petr Otahal, Stephen Wilkinson and Andrew J. Palmer

The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study pp. 459-467

Claudio Jommi, Patrizio Armeni, Margherita Battista, Paolo Procolo, Giuseppe Conte, Claudio Ronco, Mario Cozzolino, Anna Maria Costanzo, Umberto Luzio Paparatti, Gabriella Concas and Giuseppe Remuzzi

Volume 2, issue 3, 2018

Hospital Pharmacists in Europe: Between Warehouse and Prescription Pad? pp. 221-224

Livio Garattini and Anna Padula

Developing Accessible, Pictorial Versions of Health-Related Quality-of-Life Instruments Suitable for Economic Evaluation: A Report of Preliminary Studies Conducted in Canada and the United Kingdom pp. 225-231

David G. T. Whitehurst, Nicholas R. Latimer, Aura Kagan, Rebecca Palmer, Nina Simmons-Mackie, J. Charles Victor and Jeffrey Hoch

A Review of Clinical and Economic Evaluations Applied to Psychotropic Therapies Used in the Treatment of Schizophrenia in Argentina pp. 233-239

Gisela Paula González, Nebel Silvana Moscoso and Fernando Pablo Lago

The Cost Effectiveness of Lubiprostone in Chronic Idiopathic Constipation pp. 241-253

Becky Pennington, Emily-Ruth Marriott, Peter Lichtlen, Ayesha Akbar and Anthony J. Hatswell

The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study pp. 255-270

Malek B. Hannouf, Eric Winquist, Salaheddin M. Mahmud, Muriel Brackstone, Sisira Sarma, George Rodrigues, Peter K. Rogan, Jeffrey Hoch and Gregory S. Zaric

Cost Effectiveness of Stapled Haemorrhoidopexy and Traditional Excisional Surgery for the Treatment of Haemorrhoidal Disease pp. 271-280

Mary M. Kilonzo, Steven R. Brown, Hanne Bruhn, Jonathan A. Cook, Jemma Hudson, John Norrie, Angus J. M. Watson and Jessica Wood

Out-of-Pocket Expenditures, Indirect Costs and Health-Related Quality of Life of Patients with Pulmonary Tuberculosis in Thailand pp. 281-296

Pimwara Tanvejsilp, Mark Loeb, Jonathan Dushoff and Feng Xie

Healthcare Resource Uses and Out-of-Pocket Expenses Associated with Pulmonary TB Treatment in Thailand pp. 297-308

Pimwara Tanvejsilp, Mark Loeb, Jonathan Dushoff and Feng Xie

Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness Analysis pp. 309-323

Tzeyu L. Michaud, Robert L. Kane, J. Riley McCarten, Joseph E. Gaugler, John A. Nyman and Karen M. Kuntz

Impact of Fluid Choice in Systemic Inflammatory Response Syndrome Patients on Hospital Cost Savings pp. 325-335

Suzanne Laplante, Dilip U. Makhija, Sibyl H. Munson, Victor S. Khangulov, Fred W. Peyerl, Scott M. Paluszkiewicz, Aditi J. Ravindranath and Carol R. Schermer

Evaluation of Health Status of Type 2 Diabetes Outpatients Receiving Care in a Tertiary Hospital in Nigeria pp. 337-345

Maxwell Ogochukwu Adibe, Chibueze Anosike, Sunday Odunke Nduka and Abdulmuminu Isah

Cost Analysis of a Digital Health Care Model in Sweden pp. 347-354

Björn Ekman

Volume 2, issue 2, 2018

The Impact of Brexit on Pharmaceuticals and HTA pp. 87-91

Paula Lorgelly

Raise the Bar, Not the Threshold Value: Meeting Patient Preferences for Palliative and End-of-Life Care pp. 93-95

Nikki McCaffrey and Simon Eckermann

Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals pp. 97-107

Micah Rose, Stephen Rice and Dawn Craig

Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends pp. 109-123

Trevor Jozef Piatkiewicz, Janine Marie Traulsen and Tove Holm-Larsen

The Economic Burden of Small Cell Lung Cancer: A Systematic Review of the Literature pp. 125-139

Ashley Enstone, Maire Greaney, Manca Povsic, Robin Wyn, John R. Penrod and Yong Yuan

Economic Evaluation of Midazolam–Droperidol Combination, Versus Droperidol or Olanzapine for the Management of Acute Agitation in the Emergency Department: A Within-Trial Analysis pp. 141-151

Celene Y. L. Yap, Ya-seng (Arthur) Hsueh, Jonathan C. Knott, David McD Taylor, Esther W. Chan and David C. M. Kong

Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) pp. 153-163

Martina Garau, Grace Hampson, Nancy Devlin, Nicola Amedeo Mazzanti and Antonio Profico

Direct Mapping of the QLQ-C30 to EQ-5D Preferences: A Comparison of Regression Methods pp. 165-177

Ralph Crott

Cost of Intensive Care Treatment for Liver Disorders at Tertiary Care Level in India pp. 179-190

Shankar Prinja, Pankaj Bahuguna, Ajay Duseja, Manmeet Kaur and Yogesh Kumar Chawla

Resources and Costs Associated with the Treatment of Advanced and Metastatic Gastric Cancer in the Mexican Public Sector: A Patient Chart Review pp. 191-201

Miguel Quintana, José A. Toriz, Diego Novick, Kyla Jones, Brenda S. Botello and Juan Alejandro Silva

Health-Related Quality of Life in Patients Treated with Continuous Ambulatory Peritoneal Dialysis and Automated Peritoneal Dialysis in Singapore pp. 203-208

F. Yang, N. Luo, T. Lau, Z. L. Yu, M. W. Y. Foo and K. Griva

Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis pp. 209-219

Bernard Charbonnel, Dominique Simon, Jean Dallongeville, Isabelle Bureau, Sylvie Dejager, Laurie Levy-Bachelot, Julie Gourmelen and Bruno Detournay

Volume 2, issue 1, 2018

Health Technology Assessment for Policy Making in India: Current Scenario and Way Forward pp. 1-3

Shankar Prinja, Laura E. Downey, Vijay K. Gauba and Soumya Swaminathan

Application of Discrete-Choice Experiment Methods in Tobacco Control: A Systematic Review pp. 5-17

Kabindra Regmi, Dinesh Kaphle, Sabina Timilsina and Nik Annie Afiqah Tuha

Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada pp. 19-29

Graeme Ball, Feng Xie and Jean-Eric Tarride

Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data pp. 31-41

Jacqueline Nicholas, Aaron Boster, Ning Wu, Wei-Shi Yeh, Monica Fay, Jon Kendter, Ming-Yi Huang and Andrew Lee

Weighting Health Outcomes by Socioeconomic Position Using Stated Preferences pp. 43-51

Anita Lal, Mohammad Siahpush, Marjory Moodie, Anna Peeters and Robert Carter

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants pp. 53-61

Ahva Shahabi, Desi Peneva, Devin Incerti, Kimmie McLaurin and Warren Stevens

An Exploratory Study of Long-Term Publicly Waitlisted Bariatric Surgery Patients’ Quality of Life Before and 1 Year After Bariatric Surgery, and Considerations for Healthcare Planners pp. 63-76

Julie Campbell, Martin Hensher, Amanda Neil, Alison Venn, Stephen Wilkinson and Andrew J. Palmer

Reliability and Validity of the Greek Migraine Disability Assessment (MIDAS) Questionnaire pp. 77-85

Theodora Oikonomidi, Michail Vikelis, Artemios Artemiadis, George P. Chrousos and Christina Darviri

Volume 1, issue 4, 2017

Statistical Alchemy: Conceptual Validity and Mapping to Generate Health State Utility Values pp. 233-239

Jeff Round and Annie Hawton

Choosing Between Unicompartmental and Total Knee Replacement: What Can Economic Evaluations Tell Us? A Systematic Review pp. 241-253

Edward Burn, Alexander D. Liddle, Thomas W. Hamilton, Sunil Pai, Hemant G. Pandit, David W. Murray and Rafael Pinedo-Villanueva

Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR) pp. 255-263

Lisa Masucci, Jaclyn Beca, Mona Sabharwal and Jeffrey Hoch

Utilization of Intergovernmental Funds to Implement Maternal and Child Health Plans of a Multi-Strategy Community Intervention in Haryana, North India: A Retrospective Assessment pp. 265-278

Madhu Gupta, Federica Angeli, Hans Bosma, Shankar Prinja, Manmeet Kaur and Onno C. P. Schayck

Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden pp. 279-290

Ugne Sabale, Mattias Ekman, Daniel Thunström, Claire Telford and Christopher Livings

Eliciting the Monetary Value of a Quality-Adjusted Life Year in a Greek Outpatient Department in Times of Economic Austerity pp. 291-300

A. Mavrodi, V. Aletras, A. Spanou and D. Niakas

Development of a Procedure for the Government Provision of Bone-Anchored Prosthesis Using Osseointegration in Australia pp. 301-314

Laurent Frossard, Gregory Merlo, Tanya Quincey, Brendan Burkett and Debra Berg

Volume 1, issue 3, 2017

Can Price Transparency Contribute to More Affordable Patient Access to Medicines? pp. 145-147

Sabine Vogler and Kenneth R. Paterson

Model-Based Economic Evaluation of Treatments for Depression: A Systematic Literature Review pp. 149-165

Spyros Kolovos, Judith E. Bosmans, Heleen Riper, Karine Chevreul, Veerle M. H. Coupé and Maurits W. Tulder

Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology pp. 167-173

Kavisha Jayasundara, Murray Krahn, Muhammad Mamdani, Jeffrey Hoch and Paul Grootendorst

Cost-Effectiveness of Haemorrhoidal Artery Ligation versus Rubber Band Ligation for the Treatment of Grade II–III Haemorrhoids: Analysis Using Evidence from the HubBLe Trial pp. 175-184

Abualbishr Alshreef, Allan J. Wailoo, Steven R. Brown, James P. Tiernan, Angus J. M. Watson, Katie Biggs, Mike Bradburn and Daniel Hind

Evaluating the Treatment Costs for Uncomplicated Malaria at a Public Healthcare Facility in Nigeria and the Implications pp. 185-194

Charles C. Ezenduka, Daniel Resende Falleiros and Brian B. Godman

Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib pp. 195-202

Jörg Mahlich, Shinichiro Okamoto and Akiko Tsubota

Health System Efficiency: A Fragmented Picture Based on OECD Data pp. 203-221

Andreas Behr and Katja Theune

Cost-Minimisation Analysis of Erythropoiesis-Stimulating Agents in the Treatment of Anaemia in Dialysed Patients: A Pilot Study pp. 223-229

Astrid Darsonval, Virginie Besson and Claire Cavalin

Volume 1, issue 2, 2017

Model Registration: A Call to Action pp. 73-77

Christopher Sampson and Tim Wrightson

Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations pp. 79-97

Andrea Gabrio, Alexina J. Mason and Gianluca Baio

Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process pp. 99-108

Eva Kaltenthaler, Christopher Carroll, Daniel Hill-McManus, Alison Scope, Michael Holmes, Stephen Rice, Micah Rose, Paul Tappenden and Nerys Woolacott

A Comparison of Inpatient Cost Per Day in General Surgery Patients with Type 2 Diabetes Treated with Basal-Bolus versus Sliding Scale Insulin Regimens pp. 109-115

Victoria L. Phillips, Anwar L. Byrd, Saira Adeel, Limin Peng, Dawn D. Smiley and Guillermo E. Umpierrez

Cost-Benefit Analysis of Telemedicine Systems/Units in Greek Remote Areas pp. 117-121

Marios-Nikolaos Kouskoukis and Charalambos Botsaris

Utilization, Spending, and Price Trends for Quinolones in the US Medicaid Programs: 25 Years’ Experience 1991–2015 pp. 123-131

Ziyad S. Almalki, Xiaomeng Yue, Ying Xia, Patricia R. Wigle and Jeff Jianfei Guo

Early Assessment of the Likely Cost Effectiveness of Single-Use Flexible Video Bronchoscopes pp. 133-141

Christoffer Lilja Terjesen, Julia Kovaleva and Lars Ehlers

Erratum to: Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations pp. 143-143

Andrea Gabrio, Alexina J. Mason and Gianluca Baio

Volume 1, issue 1, 2017

The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review pp. 1-12

Blythe Adamson, Dobromir Dimitrov, Beth Devine and Ruanne Barnabas

Communal Sharing and the Provision of Low-Volume High-Cost Health Services: Results of a Survey pp. 13-23

Jeff Richardson, Angelo Iezzi, Gang Chen and Aimee Maxwell

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK pp. 25-36

Jameel Nazir, Malin Berling, Charles McCrea, Francis Fatoye, Sally Bowditch, Zalmai Hakimi and Adrian Wagg

Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model pp. 37-51

Barbara Graaff, Lei Si, Amanda L. Neil, Kwang Chien Yee, Kristy Sanderson, Lyle C. Gurrin and Andrew J. Palmer

A Single-Center Cost Analysis of Treating Primary and Metastatic Brain Cancers with Either Brain Laser Interstitial Thermal Therapy (LITT) or Craniotomy pp. 53-63

Eric C. Leuthardt, Jeff Voigt, Albert H. Kim and Pete Sylvester

Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review pp. 65-68

Ilke Akpinar, Philip Jacobs and Tien Dat Tran

Comment on: “Forecasting Pharmaceutical Prices for Economic Evaluations When There is No Market: A Review” pp. 69-70

Przemysław Holko

Authors’ Reply to Holko: “Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review” pp. 71-71

Ilke Akpinar, Philip Jacobs and Dat T. Tran